In this side of the Point/Counterpoint, Drs. Bernard and Flaig state that genomic testing should be routine in the management of prostate cancer patients.
Brandon Bernard, MD, MPH
Advertisement
Articles by Brandon Bernard, MD, MPH
This article summarizes the key side effects associated with ADT for the treatment of prostate cancer and discusses strategies to optimize management.
A 62-year-old man with prostate adenocarcinoma elected to proceed with radical prostatectomy as definitive management. After his pathology report showed stage IIIB disease, he elected for observation. What happened next?
Advertisement
Latest Updated Articles
Post-Prostatectomy Radiation Therapy: Patient Selection, Timing, Imaging, and Therapy IntensificationPublished: July 15th 2018 | Updated:
- Complications of Androgen Deprivation Therapy in Men With Prostate Cancer
Published: September 18th 2018 | Updated:
POINT-Prostate Cancer Genomic Analysis: Routine or Research Only?Published: December 17th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Revumenib in R/R NPM1-Mutant AML
2
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
3
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
4
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
5
